Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)-Reference-Cited by-同舟云学术

Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)

Published:2024-06-04 Issue:8 Volume:13 Page:2163-2184
ISSN:2193-8245
Container-title:Ophthalmology and Therapy
language:en
Short-container-title:Ophthalmol Ther

Author:

Giancipoli Ermete,Guglielmi Antonella^ORCID,Bux Anna Valeria,Clima Giulia Maria Emilia,Pignatelli Francesco,Boscia Francesco,Viggiano Pasquale,Boscia Giacomo,Fortunato Francesca,Besozzi Gianluca,Niro Alfredo,Dore Stefano,Iaculli Cristiana

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40123-024-00980-5.pdf

Reference33 articles.

1. Ferro Desideri L, Traverso CE, Nicolò M, Munk MR. Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics. 2023;15:1413.

2. Spooner KL, Fraser-Bell S, Hong T, Wong JG, Chang AA. Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Eye. 2022;36:1194–201.

3. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.

4. Ashraf M, Souka AAR. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye Lond Engl. 2017;31:1523–36.

5. Ohji M, et al. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther. 2020;37:1173–87.